Prospective study of fluconazole therapy in systemic neonatal fungal infection.
BACKGROUND
Standard neonatal systemic antifungal therapy with amphotericin B and flucytosine can be associated with toxicity, drug resistance and the need for prolonged venous access. There is consequently a need for alternative treatment options.


OBJECTIVE
To assess the efficacy and safety of fluconazole in the treatment of systemic neonatal fungal infections.


METHODS
Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection.


RESULTS
Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six infants died of Gram-negative bacterial infection and other intercurrent medical problems.


CONCLUSIONS
Fluconazole appeared to be safe and effective for treatment of systemic candidal infection in the neonate although more data are required in very low birth weight infants.
Wainer
S
S
Department of Paediatrics, Baragwanath Hospital, University of the Witwatersrand, South Africa.
Cooper
P A
PA
Gouws
H
H
Akierman
A
A
D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D011446:Prospective Studies
D000935:Antifungal Agents; D015725:Fluconazole